Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

3

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Arachidonate 5-lipoxygenase

3

Cyclooxygenase

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1980

3

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Idiopathic heavy menstrual blood loss

3

Juvenile arthritis

3

Osteoarthritis

3

Primary dysmenorrhea

3

Rheumatoid arthritis

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Parke Davis

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

FDA UNII

4

PUBCHEM

4

SMS_ID

4

ECHA (EC/EINECS)

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

MUSCULO-SKELETAL SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

1

TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

1

TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antiinflammatory preparations, non-steroids for topical use

1

Fenamates

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

MECLOFENAMIC ACID

48I5LU4ZWD

Export Data
Search for Structure

Status:

US Approved Rx (1986)

First approved in 1980

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Arachidonate 5-lipoxygenase

Conditions:

Idiopathic heavy menstrual blood loss

Juvenile arthritis

Primary dysmenorrhea

Rheumatoid arthritis

Meclofenamic acid, used as Meclofenamate sodium, is a non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. Meclofenamate sodium capsules are indicated for the relief of mild to moderate pain, for the treatment of pri...

mary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss; for relief of signs and symptoms of juvenile arthritis; so as for relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis. The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamate sodium was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro, meclofenamate sodium was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamate sodium. There is no evidence that meclofenamate sodium alters the course of the underlying disease.

N,N'-Carbonyldiimidazole

63A10X1FSP

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

MECLOFENAMATE SODIUM ANHYDROUS

9MMQ0YER4E

Export Data
Search for Structure

Status:

US Approved Rx (1986)

First approved in 1980

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Arachidonate 5-lipoxygenase

Conditions:

Idiopathic heavy menstrual blood loss

Juvenile arthritis

Primary dysmenorrhea

Rheumatoid arthritis

Meclofenamic acid, used as Meclofenamate sodium, is a non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. Meclofenamate sodium capsules are indicated for the relief of mild to moderate pain, for the treatment of pri...

mary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss; for relief of signs and symptoms of juvenile arthritis; so as for relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis. The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamate sodium was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro, meclofenamate sodium was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamate sodium. There is no evidence that meclofenamate sodium alters the course of the underlying disease.

MECLOFENAMATE SODIUM

94NJ818U2W

Export Data
Search for Structure

Status:

US Approved Rx (1986)

First approved in 1980

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Arachidonate 5-lipoxygenase

Conditions:

Idiopathic heavy menstrual blood loss

Juvenile arthritis

Primary dysmenorrhea

Rheumatoid arthritis

Meclofenamic acid, used as Meclofenamate sodium, is a non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. Meclofenamate sodium capsules are indicated for the relief of mild to moderate pain, for the treatment of pri...

mary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss; for relief of signs and symptoms of juvenile arthritis; so as for relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis. The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamate sodium was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro, meclofenamate sodium was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamate sodium. There is no evidence that meclofenamate sodium alters the course of the underlying disease.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1